Humacyte Inc [NASDAQ: HUMA] gained 4.08% or 0.06 points to close at $1.53 with a heavy trading volume of 4195172 shares.
It opened the trading session at $1.49, the shares rose to $1.58 and dropped to $1.485, the range by which the price of stock traded the whole day. The daily chart for HUMA points out that the company has recorded -55.39% loss over the past six months.
If we look at the average trading volume of 4.61M shares, HUMA reached to a volume of 4195172 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Humacyte Inc [HUMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $8.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 27, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 14, 2025, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise from $12 to $15, while H.C. Wainwright kept a Buy rating on HUMA stock.
The Price to Book ratio for the last quarter was 59.03, with the Price to Cash per share for the same quarter was set at 0.24.
Trading performance analysis for HUMA stock
Humacyte Inc [HUMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.13. With this latest performance, HUMA shares dropped by -35.44% in over the last four-week period, additionally sinking by -55.39% over the last 6 months – not to mention a drop of -69.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HUMA stock in for the last two-week period is set at 34.54, with the RSI for the last a single of trading hit 0.1848, and the three-weeks RSI is set at 0.2050 for Humacyte Inc [HUMA]. The present Moving Average for the last 50 days of trading for this stock 2.1769, while it was recorded at 1.5240 for the last single week of trading, and 3.0154 for the last 200 days.
Humacyte Inc [HUMA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Humacyte Inc [HUMA] shares currently have an operating margin of -13598.04% and a Gross Margin at -837.90%. Humacyte Inc’s Net Margin is presently recorded at -7461.49%.
Humacyte Inc (HUMA) Capital Structure & Debt Analysis
According to recent financial data for Humacyte Inc. ( HUMA), the Return on Equity (ROE) stands at -257.38%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -44.06%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Humacyte Inc’s Return on Invested Capital (ROIC) is -73.98%, showcasing its effectiveness in deploying capital for earnings.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
Based on Humacyte Inc’s (HUMA) latest financial statements, the Debt-to-Equity Ratio is 20.66%, indicating its reliance on debt financing relative to shareholder equity.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Humacyte Inc. (HUMA) effectively leverages its workforce, generating an average of -$277409.09 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.45% and a Quick Ratio of 1.93%, indicating strong ability to cover short-term liabilities.
Humacyte Inc [HUMA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Humacyte Inc posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HUMA.
An analysis of Institutional ownership at Humacyte Inc [HUMA]
There are presently around $36.37%, or 45.32%% of HUMA stock, in the hands of institutional investors. The top three institutional holders of HUMA stocks are: BLACKROCK INC. with ownership of 7.14 million shares, which is approximately 5.9912%. VANGUARD GROUP INC, holding 4.73 million shares of the stock with an approximate value of $$22.7 million in HUMA stocks shares; and VANGUARD GROUP INC, currently with $$13.77 million in HUMA stock with ownership which is approximately 2.4071%.
